Loading Curie Briefs...
Getting the latest healthcare news for you
Getting the latest healthcare news for you
Novo Nordisk has launched a new late-stage trial to find the lowest effective dose of its oral Wegovy (semaglutide) pill for weight loss. The study, which kicked off August 12 and runs through 2028, will enroll 450 adults with obesity. The move comes as Novo faces stiff competition from Eli Lilly in the booming obesity drug market.
Novo Nordisk is doubling down on its oral Wegovy pill, launching a new Phase 3 trial to identify the lowest dose of semaglutide that still delivers meaningful weight loss. The study, registered in a U.S. government clinical trials database, began August 12 and is expected to run until 2028 — a sign that Novo is playing the long game in a fiercely competitive obesity drug market projected to exceed $100 billion annually by 2030.
The trial comes as Novo faces mounting pressure from Eli Lilly, whose rival obesity therapies have been gaining market share. Oral Wegovy already brought in $500 million in Q2 sales, making it a critical asset for the company — and optimizing its dosing could broaden its appeal and accessibility.
By the Numbers:
Why it matters: Finding a lower effective dose could reduce side effects, lower costs, and make Wegovy more accessible to a wider patient population — potentially reshaping how clinicians approach obesity pharmacotherapy.
